ATOSSA THERAPEUTICS INC
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
ATOS$2.14+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 1. Condensed Consolidated Balance Sheets
CONDENSED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share and per share data)
| September 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $74,766 | $88,460 |
| Restricted cash | 110 | 110 |
| Prepaid materials | 1,285 | 1,487 |
| Prepaid expenses and other current assets | 950 | 2,162 |
| Total current assets | 77,111 | 92,219 |
| Investment in equity securities | — | 1,710 |
| Other assets | 2,366 | 2,323 |
| Total assets | $79,477 | $96,252 |
| Liabilities and stockholders' equity | ||
| Current liabilities | ||
| Accounts payable | $1,561 | $806 |
| Accrued expenses | 1,694 | 973 |
| Payroll liabilities | 1,061 | 1,654 |
| Other current liabilities | 1,480 | 1,803 |
| Total current liabilities | 5,796 | 5,236 |
| Total liabilities | 5,796 | 5,236 |
| Commitments and contingencies (Note 13) | ||
| Stockholders' equity | ||
| Convertible preferred stock - $0.001 par value; 10,000,000 shares authorized; 582 shares issued and outstanding as of September 30, 2024 and December 31, 2023 | — | — |
| Common stock - $0.18 par value; 350,000,000 and 175,000,000 shares authorized as of September 30, 2024 and December 31, 2023, respectively; 125,801,254 and 125,304,064 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively | 22,882 | 22,792 |
| Additional paid-in capital | 257,719 | 255,987 |
| Treasury stock, at cost; 1,320,046 shares of common stock at September 30, 2024 and December 31, 2023 | (1,475) | (1,475) |
| Accumulated deficit | (205,445) | (186,288) |
| Total stockholders' equity | 73,681 | 91,016 |
| Total liabilities and stockholders' equity | $79,477 | $96,252 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.